Saracatinib
Saracatinib is a potent ATP-competitive Src family kinase and Abl inhibitor. Src family kinases mediate integrin-dependent invasion, EGFR transactivation, and resistance to multiple targeted therapies. Saracatinib is actively investigated as a combination partner to overcome invasion-related resistance and sensitise to EGFR/VEGFR inhibitors; also evaluated in Alzheimer’s disease for tau phosphorylation biology.
Description
Scientific Overview: Saracatinib is a potent ATP-competitive Src family kinase and Abl inhibitor. Src family kinases mediate integrin-dependent invasion, EGFR transactivation, and resistance to multiple targeted therapies. Saracatinib is actively investigated as a combination partner to overcome invasion-related resistance and sensitise to EGFR/VEGFR inhibitors; also evaluated in Alzheimer’s disease for tau phosphorylation biology.
Mechanism of Action: Src / Abl Dual Kinase Inhibitor
Purity: ≥99% | Molecular Formula: C28H32ClN5O5
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | Src / Abl Dual Kinase Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C28H32ClN5O5 |
| CAS Number | 379231-04-6 |
